Sign in with Google. Opens in new tab
bullish

Alteogen Inc

Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst

Tina has highlighted this Insight as a Top Pick
677 Views23 Feb 2024 04:58
SUMMARY
  • Alteogen Inc (196170 KS) has modified the existing license agreement with Merck. Revised terms of the agreement grant Merck exclusive global right to ALT-B4 for a specific product group, pembrolizumab.
  • Under the terms of the revised agreement, Alteogen will receive an upfront payment of $20M from Merck. Alteogen will also receive additional milestone payment of up to $432M.
  • Approval of Alteogen’s first proprietary product, Tergase (expected in early 2024) will be the next major catalyst for the company.
Related Insights
More »
    Loading
Trending Collections
More »
    Loading
Trending Insights
More »
    Loading
Top Unpaywalled Insights
More »
    Loading
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
x